Morgan Stanley analyst Matthew Harrison maintained a Hold rating on Alexion Pharmaceuticals (ALXN) today and set a price target of $119.00. The company’s shares closed last Friday at $115.58.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 16.3% and a 58.9% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Freeline Therapeutics Holdings, and Global Blood Therapeutics.
Alexion Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $145.63, a 25.1% upside from current levels. In a report issued on October 28, UBS also initiated coverage with a Hold rating on the stock with a $133.00 price target.
See today’s analyst top recommended stocks >>
Based on Alexion Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $1.44 billion and GAAP net loss of $1.07 billion. In comparison, last year the company earned revenue of $1.2 billion and had a net profit of $460 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.
